Full-Time

Portfolio Strategy Operations & Management Lead

Posted on 4/10/2025

Deadline 5/30/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

Compensation Overview

$172.5k - $249.2k/yr

Senior

Cambridge, MA, USA

Category
Generalist Operations
Supply Chain Management
Operations & Logistics
Requirements
  • 5+ years of experience with Digital / Virtual Healthcare Care market & dynamics
  • 5+ years of experience with life sciences industry
  • 5+ years professional experience in investments & / or management consulting
  • Managed global projects in product dev, trial operations, or commercialization
  • Financial management, forecasting, or investment management
  • Negotiations experience
  • Working in or supporting complex matrix organization
  • Addressing and collaborating with diverse mix of functional and market experience
  • Experience collaborating with teams from multiple countries
  • A keen ability to unite diverse perspectives to work toward a shared vision. Being able to work across borders and time zones.
Responsibilities
  • Coordinate and drive geographic decisions with Global Markets teams, E.D.G.E. Regional Commercial Leads
  • Lead efforts to define & size opportunities to expand our global digital health ambition clearly understanding both potential agnostic and local market value contribution
  • Support the design, development, and maintenance of E.D.G.E. portfolio strategy in coordination with the Global Head of Digital Healthcare Portfolio Strategy & Corporate Dev and General Medicines E.D.G.E. leadership
  • With support from the E.D.G.E. PS+CD team, coalesce all dimensions of individual use cases (ie, geography, product, commercial model and implementation model) into a cohesive and operationally-sensitive roadmap
  • Clearly translate investment parameters, alongside E.D.G.E. LT, Digital, and Corporate Development Strategy Lead
  • Align on prioritized use cases with Global Markets (ie, Key, Innovate-to-Grow, Foundations), Corporate Communications & Affairs, Talent, Medical, and Finance
  • Co-lead E.D.G.E. narratives with GenMed Corporate Communications and Affairs Lead
  • Maintain a working knowledge and be considered an internal expert related to evolving market externalities, such as competitive dynamics, market consolidations, legal/regulatory changes in the digital health sector, etc.
  • With Portfolio Implementation Models Lead, bring E.D.G.E. LT together to translate each use cases into an executable roadmap
  • Empower Portfolio Operations Manager to mobilize optimal resources across the organization to execute against the roadmap
  • Co-manage resource requirements across Global E.D.G.E., alongside E.D.G.E. LT and Corporate Development Strategy Lead
  • Grow into a next-gen leader in portfolio management
  • Support development and alignment of Underserved Pop Strategy
  • Support finance, commercial leads, and product teams in developing financial models that clearly articulate the value to Sanofi shareholders
  • Diligently collect and manage resources and budget across E.D.G.E. offices
  • Help triage, solve, ad hoc, implementation challenges on a global basis
  • Gain deep familiarity of the healthcare systems in the chosen markets, to inform strategic choices with the Affiliates
  • Support agile ways of working initiatives globally and regionally.

Sanofi provides healthcare solutions through the development of treatments and vaccines. The company focuses on research and development to create new therapies for conditions like immunology, oncology, and rare diseases. Their products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. Sanofi distinguishes itself from competitors by investing heavily in scientific research and maintaining a strong pipeline of new products, as well as forming strategic partnerships. The goal of Sanofi is to improve health outcomes and enhance the quality of life for people globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi reported a 20% profit growth in Q1 2025, driven by new launches.
  • Dupixent's approval for CSU expands its market presence in immunology.
  • Tolebrutinib's potential approval could address unmet needs in multiple sclerosis.

What critics are saying

  • Increased competition in immunology may impact Dupixent's market share.
  • Potential EU regulatory delays could affect tolebrutinib's market entry.
  • Dren Bio acquisition may pose integration challenges and financial strain.

What makes Sanofi unique

  • Sanofi's Dupixent is the first targeted therapy for chronic spontaneous urticaria.
  • Tolebrutinib is a novel brain-penetrant BTK inhibitor for multiple sclerosis.
  • Sanofi's global reach allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Quantis
Apr 24th, 2025
Innate Pharma: €15M Investment by Sanofi

Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.

Yahoo Finance
Apr 24th, 2025
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%

PharmiWeb
Apr 24th, 2025
Dupixent Approved In The Us As The First New Targeted Therapy In Over A Decade For Chronic Spontaneous Urticaria

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.Kenneth MendezPresident and Chief Executive Officer at the Asthma and Allergy Foundation of America“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives. The approval of this treatment offers patients more options and the chance to control their disease.”Alyssa Johnsen, M.D., Ph.D.Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi“CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living. This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms. Dupixent has the potential to improve outcomes for CSU patients who previously had limited treatment options.”The US approval is based on data from two phase 3 clinical studies, Study A (n=136) and Study C (n=148), which included biologic-naïve patients aged 12 years and older who were symptomatic despite the use of antihistamines and assessed Dupixent as an add-on therapy to standard-of-care antihistamines, compared to antihistamines alone. Both studies met their primary and key secondary endpoints with Dupixent demonstrating reductions in itch severity and urticaria activity (a composite of itch and hives) compared to placebo at 24 weeks

PharmiWeb
Apr 9th, 2025
Tolebrutinib Phase 3 Data Published In Nejm Demonstrate Benefit On Disability Progression In Multiple Sclerosis

Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosisTolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MSTolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025; regulatory submission dossier is under review in the EU with a decision expected in Q1 2026Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS), where there are currently no treatment options approved. These findings further support the differentiated mechanism of oral, brain-penetrant tolebrutinib, targeting disability progression independent of relapse activity. These results were first presented at the ECTRIMS conference on September 20, 2024 in Copenhagen, Denmark and further analyses were also presented today during the Clinical Trials Plenary Session at the 2025 Annual Meeting for the American Academy of Neurology (AAN) in San Diego, California.Robert Fox, MDVice Chair of Research at Cleveland Clinic’s Neurological Institute, Cleveland, Ohio, US, and chair of the HERCULES global steering committee“Tolebrutinib represents a new class of therapy for the treatment of multiple sclerosis. In this large phase 3 study, tolebrutinib was found to slow the progression of disability in a subset of multiple sclerosis for which we have no approved therapies – non-relapsing secondary progressive disease. The results of this study signal a new chapter in multiple sclerosis because we finally found a potential way to treat non-relapsing secondary progressive forms.”Dr Fox is a paid advisor to Sanofi for the HERCULES study.Erik Wallström, MD, PhDGlobal Head of Neurology Development“By targeting disability progression mechanisms behind the blood-brain barrier, tolebrutinib has the potential to be a practice-changing therapeutic option for people living with multiple sclerosis

PharmiWeb
Mar 25th, 2025
Availability Of The Q1 2025 Aide Mémoire

Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website:First quarter 2025 (sanofi.com)As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's first quarter 2025 results will be published on April 24, 2025.About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | [email protected] Berland | + 1 215 432 0234 | [email protected] Obrist | + 33 6 77 21 27 55 | [email protected]éo Le Bourhis | + 33 6 75 06 43 81 | [email protected] Rouault | + 33 6 70 93 71 40 | [email protected] Gilbert | + 1 516 521 2929 | [email protected] RelationsThomas Kudsk Larsen | + 44 75 45 51 36 93| [email protected]é Kaisserian | + 33 6 47 04 12 11 | [email protected] Lauscher | + 1 908 612 7239 | [email protected] Browne | +1 781 249 1766 | [email protected] Pham | + 33 7 85 93 30 17 | [email protected] Elgoutni | + 1 617 710 3587 | [email protected] Châtelet | + 33 6 80 80 89 90 | [email protected] Li | + 33 6 84 00 90 72 | [email protected] statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended

INACTIVE